Theralase Technologies Inc (TLTFF)

[123414]

Anticipation for mice survival rates
In brain and/or lung pre clinical trials. Before or after first patient bladder cancer enrollment.

Manjunatha Ankathatti Munegowda, Ph.D., DVM, Research Scientist, Theralase discusses the potential opportunities for the Company in regards to new oncological targets, such as Glio Blastoma Multiforme (“GBM”), a deadly form of brain cancer, and Non-Small Cell Lung Cancer (“NSCLC”) –

https://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=7909670196872586&topic=TLTFF&symbology=null&cp=null&webmasterId=90338
June 29, 2018 - 7:00 AM EDT